MAPK8 and metabolic disease: The mitogen-activated protein (MAP) kinase family member c-Jun-N-terminal kinase (JNK) has been shown to be a therapeutic target for a variety of diseases including neurodegeneration, metabolic disorders, inflammation, cardiovascular disease, and cancer.